Search PubMed⌕ Search

Biomedical subjects

T Uchida

Publications and source records attributed to T Uchida.

At least 415 records · Page 23Linked to original sources
PubMed1996

[A case of solitary metastasis from renal cell carcinoma to the thyroid gland].

A case of solitary metastasis with renal cell carcinoma to the thyroid gland is presented. The patient was a 54-year-old man found to have an abnormal mass in the neck. He had a past history of radical nephrectomy orignating from the right renal cell carcinoma 5 years earlier (pT2N0M0, G2 > 3, alveolar type, clear cell subtype). Ultrasonography revealed a tumor mass in the right hemithyroid gland. Right hemithyroidectomy was performed on April 19, 1995. Histopathologically, the removed thyroid tumor showed clear cell carcinoma. The possibility of a primary thyroid tumor was ruled out by immunohistochemical thyroglobulin staining, and the present case was thus diagnosed as of metastatic thyroid tumor of renal cell carcinoma. The present case is the 12th case of thyroid solitary metastasis of renal cell carcinoma reported in Japan to date.

Carcinoma, Renal Cell↗
PubMed1996

[Renal cell carcinoma in childhood: a case report].

A case of renal cell carcinoma (RCC) in a teenage patient is reported. A 13-year-old girl visited our hospital with the complaint of dyspnea and right abdominal mass. CT scan and chest X-P revealed a right renal tumor with multiple lung metastasis. Wilms' tumor was suspected and a combination chemotherapy consisting of actinomycin D and vincristin was performed. Since the tumor was insensitive to these agents, open biopsy was done. The pathological findings showed clear cell renal cell carcinoma. Despite the administration of alpha interferon, 5-FU and cimetidine, the disease was progressive and the patient died 5 months after diagnosis. It is important to consider the possibility of renal cell carcinoma in teenage patients with a renal mass, since more than 40% of the renal tumors in this age group are renal cell carcinomas.

Adolescent↗
PubMed1996

[Clinical efficacy of fluconazole against fungal infections in hematological diseases].

Clinical efficacy of fluconazole was evaluated against fungal infections complicated with hematological diseases. Fluconazole 200 approximately 400 mg was administered intravenously to 20 suspected fungal infections occurring in patients with hematological diseases (acute leukemia 6, malignant lymphoma 11, adult T cell leukemia 2, chronic myelogenous leukemia blastic crisis 1). These mycoses included 8 cases of suspected pulmonary fungal infection, 10 cases suspected fungemia, and two cases of suspected hepatic fungal abscess. The clinical response rate was 60.0%. Side effects were observed in two cases, one with transient liver function test abnormality and the other with nausea. Fluconazole is considered to be a potent, safe antifungal agent for the treatment of suspected fungal infections associated with hematological diseases.

Adult↗
PubMed1996

[Changes of coronary artery diameter during follow-up in patients with vasospastic angina: comparison of spastic and non-spastic sites].

The relationship between coronary vasospasticity and the development of atherosclerotic lesion was studied in 24 patients with vasospastic angina. All patients had no organic stenosis initially and underwent follow-up coronary angiography at 66 +/- 9 months after the initial examination. The coronary artery diameter was measured with the contour detection method. The spastic and non-spastic sites were identified at the initial coronary angiography with the acetylcholine provocation test. The change of the luminal diameter (delta LD) and the ratio of the change of luminal diameter (% delta LD) were compared at the spastic and the non-spastic sites. The follow-up examination showed significant decreases of coronary artery diameter in both the spastic (2.35 +/- 0.67 vs 2.16 +/- 0.58 mm, p < 0.001) and non-spastic sites (2.66 +/- 0.91 vs 2.54 +/- 0.84 mm, p = 0.02). However, delta LD and % delta LD were not different between the spastic and non-spastic sites (delta LD: -0.19 +/- 0.40 vs -0.12 +/- 0.46 mm, NS; % delta LD: -6.7 +/- 14.8% vs -3.2 +/- 17.0%, NS). In conclusion, coronary vasospasticity does not promote the development of atherosclerotic lesion.

Aged↗
PubMed1996

[Reevaluation of administration dosage in parenteral iron therapy].

Concerning parenteral iron therapy in iron deficiency anemia, Nakao's formula has been used to calculate the total amount of iron to be given, based on 80 ml/kg of circulating blood volume and 17 mg/kg of storage iron in healthy Japanese. Recent studies using radionuclide and radioimmunoassay revealed 65 ml/kg as the circulating blood volume and 500 mg as storage iron. From these data, the total amount of iron can be calculated from the following formula; 3.4 (16-X) x 65 x body weigh/100 + 500 mg (B) where 3.4 is the conversion factor for grams of hemoglobin to mg iron and X is the hemoglobin value before treatment. Parenteral iron therapy was performed in 15 patients with iron deficiency anemia using a total dose of iron calculated by the above the formula (B). The results were effective, and no decrease of hemoglobin was seen except in cases with continuous bleeding. In such cases, iron doses depending upon the amount of continuous bleeding should be added to the total amounts obtained from formula (B).

Adult↗
PubMed1996

Palmar dislocation in the metacarpophalangeal joint of the thumb--a case report.

A 19-year-old male sustained forced hyperflexion of his right thumb in a motorcycle accident which resulted in a palmar dislocation of the metacarpophalangeal joint. Open reduction was performed which confirmed the rupture of the palmar plate. Dislocation recurred post-operatively. A second operation was carried out, at which time rupture of the radial collateral ligament and dorsal capsule was recognised. Postoperative joint movement was within an acceptable range. However, radiographic examination revealed persistent subluxation. This result was thought to be related to the shape of the head of the first metacarpal bone.

Accidents, Traffic↗
PubMed1996

Antitumor activities of combined treatment with a novel immunomodulator, (2S,3S,4R)-1-O-(alpha-D-Galactopyranosyl)-2-(N-Hexacosanoylamino)-1,3,4 - octadecanetriol (KRN7000), and radiotherapy in tumor-bearing mice.

The novel immunomodulator (2S,3S,4R)-I-O-(alpha-D-galactopyranosyl)-2- (N-hexacosanoylamino)-1,3,4-octadecanetriol (KRN7000) in combination with high-dose (20 and 30 Gy) local x-ray irradiation or low-dose (3 Gy) fractionated whole-body irradiation showed significantly stronger antitumor activities against Meth A-and Colon26-bearing mice than treatments by radiation or KRN7000 alone, and 60% of mice in combination treatment groups were cured. Furthermore, the results of tests rechallenging the cured mice with Meth A and Colon26 cells strongly suggested that tumor-specific immunity was induced by the combination treatment. The suggestion was supported by the result that the systemic administration of KRN7000 could produce large amounts of interleukin-2 and interferon-gamma, which contribute to induction of tumor-specific cytotoxic lymphocytes not only in normal mice but also in whole-body irradiated mice. Furthermore, it was also suggested that KRN7000 contributes to protecting antitumor effector cells, such as natural killer cells, from impairments caused by radiation. Taking together the results and the knowledge that tumor-specific cytotoxic lymphocytes play a critical role in prevention of tumor recurrence and distant metastasis, it is strongly suggested that combined therapy with KRN7000 and radiation could be quite useful for cancer treatment.

Adjuvants, Immunologic↗
PubMed1996

[A case of congenital penile curvature].

A case of congenital penile curvature is reported. A 21-year-old man was admitted because of penile pain curvature to the left at the erection and the difficulty of intercourse. He had no signs of Peyronie's disease and no history of penile fracture so that he was considered to have congenital penile curvature. By Nesbit's method the curvature of the penis was appropriately corrected. There were no signs of recurrence at either 1 or 5 months after the operation.

Adult↗
PubMed1996

[Administration of oral etoposide for one year as adjuvant chemotherapy for non-small cell lung cancer-side effect].

The possibility of using etoposide 25 mg daily as adjuvant chemotherapy for non-small cell lung cancer was discussed. Initially, 73 patients who had undergone resection participated in this trial; 49 of them were eligible, 24 including a patient over 70 years of age (8) took the drug for 1 year, 22 patients resigned from the study due to side effects, and a further 3 patients died during the trial. The main side effects observed were gastro-intestinal trouble (13) and pneumonia (4). The side effects of this drug appeared early in the treatment phase. During the first month of treatment, 9 patients discontinued the drug due to side effects, and 10 more did so within 4 months. To achieve optimal conditions for the trial study of low-dose etoposide it was found important to select patients under 70 years of age and to control side effects of the drug on the gastro-intestinal tract from the beginning.

Administration, Oral↗
PubMed1996

[Assistance to enhance the use of home helper services for the cancer patient].

For the end-stage cancer patient to live at home with his or her quality of life (QOL) sustained, Home Helper Services are considered effective. In fact, however, many do not avail themselves of such services. Since the disease situation is apt to change dramatically, it is difficult to predict the length of time of care at home, and the patient's family does not tend to utilize such services unless the patient is completely bedridden. Short-term use or the difficulty or rapid response of such services has been among the reasons given of this. Given this background, there appears to be a need for suitable assessment in dealing quickly with possible disabilities which might occur and a number of occupations. Also, when considering home medical care for the cancer patient, an administrative system capable of a rapid response when problems of this kind occur is indispensable. Working on the administration to fulfill this need is also the task of the professionals in this field.

Adolescent↗
PubMed1996

[CD2 and CD8 expression in acute promyelocytic leukemia].

A 34-year-old man was admitted to our hospital for a headache in March, 1995. The patient's hemoglobin was 7.5 g/dl, platelet count was 1.8 x 10(4)/microliter and white blood cell (WBC) count was 12,400/microliters with 99% myeloblasts. Myeloblasts were agranular or hypogranular but electron microscopy revealed microgranules in cytoplasm, and a few faggots were observed. The bone marrow was hyperplastic due to myeloblasts and chromosomal abnormality was recognized: 46, XY, t(15; 17) (q22; q12). PML-RAR alpha with intron 3 breakpoint of the PML locus, and rearrangements of the T-cell receptor beta and gamma genes were detected. These cells were positive for CD2 (63%), CD8 (47%), CD13 (87%) and CD33 (99%). Microgranular variant type of acute promyelocytic leukemia (APL) was diagnosed. Disseminated intravascular coagulation (DIC) was also present. The patient was treated with enocitabine, daunorubicin, 6-mercaptopurine, dalteparin sodium, anti-thrombin III concentrates and gabexate mesilate with prophylactic frozen transfusions of fresh plasma and platelet transfusions for 5 days, but WBC count did not decrease and DIC did not improve. The patient died of cerebral hemorrhage 7 days after diagnosis of APL. APL with CD8 expression has never been reported. We suggest that therapy should be modified in this type of APL and conclusions concerning the most appropriate therapeutic strategy will depend on the results of treatment of similar cases in the future.

Adult↗
PubMed1995

Analysis of phosphorylation of tau with antibodies specific for phosphorylation sites.

Previously, we determined sites of tau protein phosphorylation by tau protein kinase (TPK) I/glycogen synthase kinase 3 beta (GSK-3 beta) and TPKII/(cyclin-dependent kinase 5 (CDK5) + p23). We prepared antibodies specific for these sites of tau phosphorylated by TPKI and TPKII, using chemically synthesized phosphopeptides as antigens. Each antibody specifically reacts with each phosphorylation site. With these antibodies, it was confirmed that TPKI and TPKII are responsible for these phosphorylation sites, as reported previously, except that Ser404 is also weakly phosphorylated by TPKI alone. It was also observed that TPKII-phosphorylation enhances TPKI-phosphorylation. These results indicate that these antibodies are useful tools for investigation of the phosphorylation of tau by TPKI and TPKII.

Amino Acid Sequence↗
PubMed1995

In situ dephosphorylation of tau by protein phosphatase 2A and 2B in fetal rat primary cultured neurons.

Using antibodies recognizing the phosphorylation state of specific sites, phosphorylation states of tau were monitored in fetal rat primary cultured neurons. When cultured neurons were treated with okadaic acid (OA) or calyculin A (CalA) at concentrations sufficient to inhibit protein phosphatase 2A (PP2A), phosphorylation of Ser-199/Ser-202 (numbered according to the human tau 441) and Ser-235 increased. On the other hand, treatment with Ca2+ ionophore, A23187, induced dephosphorylation of Ser-199/Ser-202, Thr-205, Ser-396 and Ser-404, and this dephosphorylation was repressed by inhibitors of protein phosphatase 2B (PP2B), cyclosporin A and FK506. These results indicate that PP2A and PP2B are differentially involved in dephosphorylation of tau in neurons.

Animals↗
PubMed1995

Crystal structure of Ustilago sphaerogena ribonuclease U2 at 1.8 A resolution.

The crystal structure of purine-specific ribonuclease (RNase) U2 from Ustilago sphaerogena has been solved by the molecular replacement methods using RNase T1 as a search model. The structure, with 114 amino acid residues, 141 water molecules, and a sulfate ion, is refined to an R factor of 0.143 at 1.8 A resolution. As evidenced by the electron densities, residues 49 and 50 are revised to Glu 49 and Asp 50, respectively, and also Asp 45 is identified as a beta-isomerized form to L-isoaspartate with a beta-peptide linkage. RNase U2 consists of a beta-hairpin at residues from 7 to 14, a 4.4-turn alpha-helix from 16 to 32, a central beta-sheet with five strands, and a protruding beta-turn from 74 to 77. As for the catalytic site residues, His 41, Glu 62, and Arg 85 are located as constituents of the central beta-sheet, and Tyr 39 and His 101 are situated at either end of the beta-sheet. The side chains of Tyr 39, Glu 62, Arg 85, and His 101 are hydrogen-bonded to the sulfate ion which marks the RNA phosphate position. Though the side chain of His 41 is pointing away from the sulfate, small conformational adjustments of His 41 enable the side chain to interact with either the phosphate or the ribose group of RNA. The loop region from Tyr 44 to Asp 50 is ascribed to the base recognition site where Glu 49 is involved in adenine recognition. beta-Isomerized Asp 45 suggests that this region is conformationally flexible and alterable.

Amino Acid Sequence↗
PubMed1995

Cloning and expression of human uridine phosphorylase.

Using a mouse cDNA probe we have identified a human uridine phosphorylase cDNA clone from the cDNA library of a human colorectal tumor cell line, HCT116. The recombinant human uridine phosphorylase expressed in COS-7 cells demonstrated specific enzyme activity with uridine as the substrate; this activity was inhibited by the competitive inhibitor 2,2'-anhydro-5-ethyluridine. Northern blot analysis with the cDNA as a probe demonstrated high levels of mRNA expression in several tumor cell lines but very low level in normal cell, WI-38. The expression of uridine phosphorylase mRNA in HCT-116 cells was further enhanced by treating the cells with vitamin D3 and the inflammatory cytokines: tumor necrosis factor alpha, interleukin 1 alpha and interferon gamma.

Amino Acid Sequence↗
PubMed1995

Evaluation of lumbar spine fusion. Plain radiographs versus direct surgical exploration and observation.

STUDY DESIGN: In a retrospective study, the incidence of false positive and false negative interpretation of x-rays for solid spinal arthrodesis with spinal instrumentation was evaluated in 75 patients. OBJECTIVE: To evaluate the accuracy of the interpretation of x-rays for diagnosing solid spinal arthrodesis in patients with spinal instrumentation. SUMMARY OF BACKGROUND DATA: This retrospective study compared spinal fusion, as determined by direct observation and radiographic evaluation, in 75 patients with instrumented lumbar fusions using multiple devices. The fusions included posterolateral fusions or posterolateral with interbody fusions. Autograft, allograft, and a combination of these also were used. METHODS: A single blinded examiner reviewed all x-rays immediately before the spinal hardware was removed and the fusion mass was explored by the surgeon. RESULTS: There was a positive correlation between x-rays and the observations at the time of surgery in only 68% of the patients. CONCLUSION: This study indicates that the accuracy of x-ray interpretation for spinal arthrodesis is only 68%. The L4-L5 level was the most difficult level to fuse and the most difficult to interpret using x-rays. Patients with persistent back pain, when nonmechanical causes have been ruled out, should be considered for surgical exploration of the fusion mass even if x-rays appear to indicate a solid fusion.

False Negative Reactions↗
PubMed1995

Mutational analysis of the CDKN2 (MTS1/p16ink4A) gene in primary B-cell lymphomas.

The CDKN2 gene located on chromosome 9p21 encodes the cyclin-dependent kinase-4 inhibitor p16. This gene is a putative tumor-suppressor gene because of its frequent alterations in many kinds of tumor cell lines. We analyzed the CDKN2 gene to evaluate its alterations in 52 primary specimens of non-Hodgkin's lymphoma (NHL) or chronic lymphocytic leukemia (CLL) of B-cell origin by Southern blot analysis, polymerase chain reaction-mediated single-strand conformation polymorphism (PCR-SSCP) analysis, and direct sequencing. By Southern blot analysis, we showed homozygous deletion of the CDKN2 gene in 3 of 42 patients with B-NHL (7.1%). After screening by PCR-SSCP analysis, direct sequencing identified one missense mutation at codon 72 (nucleotide 233) and two frameshifts due to a 35-bp deletion arising at codon 49 (nucleotides 163 to 175) in patients with B-NHL (3 of 42, 7.1%). In the patient carrying the missense mutation, hemizygous deletion of the CDKN2 gene was also suspected. In this study, we detected alterations in CDKN2 in 6 of 42 patients (14.3%) with B-NHL and in none of 10 patients with B-CLL. Our results suggest that the CDKN2 alterations contribute in tumorigenesis in some patients with B-NHL.

Adolescent↗